checkAd

     145  0 Kommentare Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000

    KELOWNA, BC / ACCESSWIRE / November 20, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases …

    KELOWNA, BC / ACCESSWIRE / November 20, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that it has closed its previously announced private placement (the "PrivatePlacement") of unsecured convertible notes (the "Notes") for aggregate gross proceeds of AUD$3,215,000 which represents an oversubscription of AUD$215,000 above its previously announced minimum placement of AUD$3,000,000. Recently appointed, Chief Executive Officer, Mr. Jason Carroll, participated in the Private Placement with an investment of AUD$325,000.

    The proceeds of the Private Placement will be used to advance Tryp's research and development programs and for general working capital purposes. Commenting on the Private Placement, Mr. Carroll said, "The Tryp Therapeutics team are delighted to announce this successful funding round, a testament to the confidence our investors have in Tryp's vision and capability. This investment is a vital step that will enable our team to accelerate the progress of our clinical programs for the ultimate benefit of patients."

    ACNS Capital Markets Pty Ltd trading as Alto Capital ("Alto Capital") acted as lead manager for the Private Placement in accordance with the terms of an engagement letter between Alto Capital and the Company (the "Engagement Agreement") pursuant to which Alto Capital is entitled to a cash fee of 6% of proceeds raised under the Private Placement and will be issued such number of warrants as equals to 4.0% of the Common Shares issuable on conversion of the Notes.

    Closing of the Private Placement is subject to final approval by the Canadian Securities Exchange (the "CSE"). The securities issued in the Private Placement, including the common shares issuable on conversion of the Notes, will be subject to a hold period of four months and one day from the closing date of the Private Placement in accordance with applicable securities laws.

    Lesen Sie auch

    The Private Placement constitutes a "related party transaction" as such term is defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101") as an Officer of the Company has participated in the Private Placement, acquiring aggregate principal amount of AUD$325,000 of Notes on the same basis as other subscribers. In addition, a director is entitled to receive certain fees from Alto Capital in connection with the Private Placement and the transactions contemplated in the Engagement Agreement. The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the Private Placement as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related party, exceeded 25% of the Company's market capitalization (as determined under MI 61-101). Further details will be included in a material change report to be filed by the Company. The Private Placement was approved by the board of directors of the Company.

    Seite 1 von 4



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000 KELOWNA, BC / ACCESSWIRE / November 20, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases …

    Schreibe Deinen Kommentar

    Disclaimer